Journal of pharmaceutical and biomedical analysis最新文献

英文中文

Exploring the mechanism of action of Bailemian capsule in the treatment of insomnia based on metabolomics, 16S rRNA with UPLC-QE-Orbitrap-MS/MS

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis

Pub Date : 2025-02-05 DOI: 10.1016/j.jpba.2025.116733

Yuelin Bi , Peng Wang , Wanting Ye , Shiyun Zhang, Yang Bai, Haoran Xu, Gengyuan Yu, Tonghua Zhang, Jiaqi Wang, Ying Liu, Yikun Sun

Bailemian capsule (BLMC) is composed of lily bulb, thorny Acanthopanax root, and other traditional Chinese medicines; it is commonly used to treat insomnia in traditional Chinese medicine. However, the active ingredients and mechanisms of action that underlie this treatment ability have not been fully explored. Here, a liquid chromatography-tandem mass spectrometry method was developed to qualitatively analyse the exogenous BLMC components that directly entered the blood and several brain regions after administration of BLMC to mice. A total of 47 compounds that directly entered the blood, including isoleucine. Moreover, there were 33, 34, 36, and 27 compounds distributed in the hypothalamus, hippocampus, frontal cortex, and temporal cortex of the mice, respectively. Subsequently, this study integrated network pharmacology, metabolomics and gut microbiota analysis to explore potential mechanism of BLMC against insomnia. The network pharmacology results suggest that BLMC affects insomnia by modulating the glutamatergic synaptic pathway. And serum and hypothalamic metabolomics analysis indicates that BLMC mainly regulates the metabolic pathways of D-Glutamine and D-Glutamic acid metabolism, significantly upregulating the differential metabolite glutamic acid and downregulating glutamine. In addition, analysis of gut microbiota indicates a close relationship between norank_f_Desulfovibirosaceae and glutamic acid. This study systematically revealed for the first time the potential pharmacological components of BLMC in treating insomnia, and explored its mechanism of action from multiple perspectives, laying the foundation for further exploration of the mechanism of BLMC in treating insomnia.

{"title":"Exploring the mechanism of action of Bailemian capsule in the treatment of insomnia based on metabolomics, 16S rRNA with UPLC-QE-Orbitrap-MS/MS","authors":"Yuelin Bi , Peng Wang , Wanting Ye , Shiyun Zhang, Yang Bai, Haoran Xu, Gengyuan Yu, Tonghua Zhang, Jiaqi Wang, Ying Liu, Yikun Sun","doi":"10.1016/j.jpba.2025.116733","DOIUrl":"10.1016/j.jpba.2025.116733","url":null,"abstract":"<div><div>Bailemian capsule (BLMC) is composed of lily bulb, thorny <em>Acanthopanax</em> root, and other traditional Chinese medicines; it is commonly used to treat insomnia in traditional Chinese medicine. However, the active ingredients and mechanisms of action that underlie this treatment ability have not been fully explored. Here, a liquid chromatography-tandem mass spectrometry method was developed to qualitatively analyse the exogenous BLMC components that directly entered the blood and several brain regions after administration of BLMC to mice. A total of 47 compounds that directly entered the blood, including isoleucine. Moreover, there were 33, 34, 36, and 27 compounds distributed in the hypothalamus, hippocampus, frontal cortex, and temporal cortex of the mice, respectively. Subsequently, this study integrated network pharmacology, metabolomics and gut microbiota analysis to explore potential mechanism of BLMC against insomnia. The network pharmacology results suggest that BLMC affects insomnia by modulating the glutamatergic synaptic pathway. And serum and hypothalamic metabolomics analysis indicates that BLMC mainly regulates the metabolic pathways of D-Glutamine and D-Glutamic acid metabolism, significantly upregulating the differential metabolite glutamic acid and downregulating glutamine. In addition, analysis of gut microbiota indicates a close relationship between <em>norank_f_Desulfovibirosaceae</em> and glutamic acid. This study systematically revealed for the first time the potential pharmacological components of BLMC in treating insomnia, and explored its mechanism of action from multiple perspectives, laying the foundation for further exploration of the mechanism of BLMC in treating insomnia.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"258 ","pages":"Article 116733"},"PeriodicalIF":3.1,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterization of trimethylamine metabolic pathways using pseudo-targeted metabolomics

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis

Pub Date : 2025-02-04 DOI: 10.1016/j.jpba.2025.116737

Xin-Nan Wang , Jian-Qun Liu , Wen-Liang Ji , Zong-Li Huo , Li-Fang Liu , Jia-Yi Zheng

Trimethylamine (TMA) metabolism comprises choline-containing compounds’ metabolization, TMA production and trimethylamine N-oxide (TMAO) generation. However, the presence of numerous compounds in the carnitine and phosphatidylcholine (PC) pool compositions complicates profiling work significantly. This study is aimed at developing an efficient method for profiling TMA metabolic pathways, including quantifying known compounds and semi-quantifying the differential metabolites in the carnitine and PC pool compositions. Pseudo-targeted metabolomics is applicable for characterization. Firstly, multivariate statistics were performed to identify valuable metabolites (variable importance in the projection ＞1) from quality control biological samples. Given that TMA metabolism involved in host-gut microbiota interaction, co-metabolites were defined as the intersections of valuable metabolites from different biological samples (serum, liver, and intestinal contents) and further screened. Finally, alterations in TMA metabolism were observed in dextran sulfate sodium-induced colitis, with semi-quantitative analysis for excavated co-metabolites including 11 PCs, 6 lyso-phosphatidylcholines, and 2 acylcarnitines and quantitative analysis for 10 known metabolites. The findings revealed increased TMA production and accumulation of choline-containing compounds in the gut during ulcerative colitis exacerbation. Correspondingly, the circulating level of TMAO was elevated in the colitis group. A comprehensive understanding of TMA metabolism can contribute to disease differential diagnoses and potential mechanism studies.

{"title":"Characterization of trimethylamine metabolic pathways using pseudo-targeted metabolomics","authors":"Xin-Nan Wang , Jian-Qun Liu , Wen-Liang Ji , Zong-Li Huo , Li-Fang Liu , Jia-Yi Zheng","doi":"10.1016/j.jpba.2025.116737","DOIUrl":"10.1016/j.jpba.2025.116737","url":null,"abstract":"<div><div>Trimethylamine (TMA) metabolism comprises choline-containing compounds’ metabolization, TMA production and trimethylamine N-oxide (TMAO) generation. However, the presence of numerous compounds in the carnitine and phosphatidylcholine (PC) pool compositions complicates profiling work significantly. This study is aimed at developing an efficient method for profiling TMA metabolic pathways, including quantifying known compounds and semi-quantifying the differential metabolites in the carnitine and PC pool compositions. Pseudo-targeted metabolomics is applicable for characterization. Firstly, multivariate statistics were performed to identify valuable metabolites (variable importance in the projection ＞1) from quality control biological samples. Given that TMA metabolism involved in host-gut microbiota interaction, co-metabolites were defined as the intersections of valuable metabolites from different biological samples (serum, liver, and intestinal contents) and further screened. Finally, alterations in TMA metabolism were observed in dextran sulfate sodium-induced colitis, with semi-quantitative analysis for excavated co-metabolites including 11 PCs, 6 lyso-phosphatidylcholines, and 2 acylcarnitines and quantitative analysis for 10 known metabolites. The findings revealed increased TMA production and accumulation of choline-containing compounds in the gut during ulcerative colitis exacerbation. Correspondingly, the circulating level of TMAO was elevated in the colitis group. A comprehensive understanding of TMA metabolism can contribute to disease differential diagnoses and potential mechanism studies.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"258 ","pages":"Article 116737"},"PeriodicalIF":3.1,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143289646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of human UDP-glucuronosyltransferases involved in I3,II8-biapigenin glucuronidation in Vitro

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis

Pub Date : 2025-02-04 DOI: 10.1016/j.jpba.2025.116735

Ming Li , Hua Sun , Jin-Ling Song , Xing Sun , Wei Li

I3,II8-biapigenin is a biflavonoid compound with diverse pharmacological effects. The present study aimed to investigate the glucuronidation of I3,II8-biapigenin in the human liver microsomes (HLMs) and recombinant human UDP-glucuronosyltransferases (UGTs). Three glucuronidation metabolites of I3,II8-biapigenin were detected in HLMs. Both recombinant human UGTs and chemical inhibitors studies demonstrated that UGT1A1, UGT1A3, UGT1A9 and UGT1A10 were involved in the glucuronidation of I3,II8-biapigenin. The present investigation provided information for the drug-drug interaction potentials of I3,II8-biapigenin when co-administrated with UGTs inhibitors or inducers.

引用次数: 0

Exploring the mechanisms of Yinchenhao decoction against ANIT-induced cholestatic liver injury by lipidomics, metabolomics and network pharmacology

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis

Pub Date : 2025-02-04 DOI: 10.1016/j.jpba.2025.116736

Weiwei Li , Jing Zhu , Ting Zhou , Ziwen Jin

Yinchenhao decoction (YCHD) has been used for the treatment of cholestasis for more than 1000 years with clear clinical efficacy. However, its active compounds and pharmacological mechanism against cholestasis are unclear. In this study, an integrated strategy of network pharmacology, lipidomics, metabolomics, and molecular docking were performed to elucidate the mechanism of YCHD’s anti-cholestasis effect. Network pharmacology demonstrated YCHD mainly modulated lipid and atherosclerosis signaling pathways with the involvement of NF-κB, TNF, MAPK, and PI3K/AKT signaling pathways. In vivo experiments, male C57BL/6 J mice model of cholestasis was established by alpha-naphthyl isothiocyanate (ANIT), and were treated with different dosages (3 g/kg and 9 g/kg) of YCHD for one week. Ursodeoxycholic acid (UDCA) was used as a positive control. The in vivo experiments verified the ameliorative effect of YCHD on inflammation, hepatocellular injury and cholestasis. Furthermore, lipidomics and metabolomics research showed that YCHD could improve the metabolism disorder of glycerolipid, glycerophospholipid and amino acids. Subsequently, further WB and molecular docking validation experiments showed that the active compounds in YCHD have regulatory effects on the PPARγ/NF-κB/JNK pathway, the core pathway in lipid and atherosclerosis pathways, thereby inhibiting inflammatory response and improving lipid metabolism disorders. This study could provide evidence of the molecular mechanism and material basis of YCHD in treating cholestasis. This study also provided new research ideas for the discovery of active ingredients in traditional Chinese medicine formulas for the treatment of cholestasis.

{"title":"Exploring the mechanisms of Yinchenhao decoction against ANIT-induced cholestatic liver injury by lipidomics, metabolomics and network pharmacology","authors":"Weiwei Li , Jing Zhu , Ting Zhou , Ziwen Jin","doi":"10.1016/j.jpba.2025.116736","DOIUrl":"10.1016/j.jpba.2025.116736","url":null,"abstract":"<div><div>Yinchenhao decoction (YCHD) has been used for the treatment of cholestasis for more than 1000 years with clear clinical efficacy. However, its active compounds and pharmacological mechanism against cholestasis are unclear. In this study, an integrated strategy of network pharmacology, lipidomics, metabolomics, and molecular docking were performed to elucidate the mechanism of YCHD’s anti-cholestasis effect. Network pharmacology demonstrated YCHD mainly modulated lipid and atherosclerosis signaling pathways with the involvement of NF-κB, TNF, MAPK, and PI3K/AKT signaling pathways. In <em>vivo</em> experiments, male C57BL/6 J mice model of cholestasis was established by alpha-naphthyl isothiocyanate (ANIT), and were treated with different dosages (3 g/kg and 9 g/kg) of YCHD for one week. Ursodeoxycholic acid (UDCA) was used as a positive control. The <em>in vivo</em> experiments verified the ameliorative effect of YCHD on inflammation, hepatocellular injury and cholestasis. Furthermore, lipidomics and metabolomics research showed that YCHD could improve the metabolism disorder of glycerolipid, glycerophospholipid and amino acids. Subsequently, further WB and molecular docking validation experiments showed that the active compounds in YCHD have regulatory effects on the PPARγ/NF-κB/JNK pathway, the core pathway in lipid and atherosclerosis pathways, thereby inhibiting inflammatory response and improving lipid metabolism disorders. This study could provide evidence of the molecular mechanism and material basis of YCHD in treating cholestasis. This study also provided new research ideas for the discovery of active ingredients in traditional Chinese medicine formulas for the treatment of cholestasis.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"258 ","pages":"Article 116736"},"PeriodicalIF":3.1,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143289644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High throughput analysis of vancomycin in human plasma by UHPLC-MS/MS

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis

Pub Date : 2025-02-04 DOI: 10.1016/j.jpba.2025.116729

Xiaoqian Chen , Luyao Yu , Yingxia Guo , Jiansong You , Meiyun Shi , Yalin Xi , Lei Yin

An analytical assay based on ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) technique for absolute quantification of vancomycin in complexed biological matrix was developed in this study. Reversed phase column with gradient elution was chosen for chromatographic separation of vancomycin and internal standard (IS) norancomycin. Sample pretreatment was performed by micro-solid phase extraction (μ-SPE) with Oasis® MAX μElution Plate (I.D., 30 μm). Multiple reaction monitoring (MRM) transition was chosen for monitoring of the analytes. For vancomycin, mass-to-charge ratio (m/z) of the MRM transition was 725.3→144.1; For norvancomycin, m/z of the MRM transition was 718.3→144.2. The running time was 3 minutes for each sample. The UHPLC-MS/MS method showed a good linear relationship (R²≥0.995) in the concentration range of 0.5–100 μg/mL. The intra- and inter-day accuracies (relative error, RE) are within the range of −3.44 %-1.50 % and precisions are between 3.48 % and 10.19 %. μ-SPE could enrich the analytes and decrease the endogenous interferences, thereby improving the selectivity and sensitivity of the method. The analytical assay is selective, accurate and reproducible. The assay was successfully applied to therapeutic drug monitoring of vancomycin in clinical application.

{"title":"High throughput analysis of vancomycin in human plasma by UHPLC-MS/MS","authors":"Xiaoqian Chen , Luyao Yu , Yingxia Guo , Jiansong You , Meiyun Shi , Yalin Xi , Lei Yin","doi":"10.1016/j.jpba.2025.116729","DOIUrl":"10.1016/j.jpba.2025.116729","url":null,"abstract":"<div><div>An analytical assay based on ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) technique for absolute quantification of vancomycin in complexed biological matrix was developed in this study. Reversed phase column with gradient elution was chosen for chromatographic separation of vancomycin and internal standard (IS) norancomycin. Sample pretreatment was performed by micro-solid phase extraction (μ-SPE) with Oasis® MAX μElution Plate (I.D., 30 μm). Multiple reaction monitoring (MRM) transition was chosen for monitoring of the analytes. For vancomycin, mass-to-charge ratio (<em>m/z</em>) of the MRM transition was 725.3→144.1; For norvancomycin, <em>m/z</em> of the MRM transition was 718.3→144.2. The running time was 3 minutes for each sample. The UHPLC-MS/MS method showed a good linear relationship (R<sup>2</sup>≥0.995) in the concentration range of 0.5–100 μg/mL. The intra- and inter-day accuracies (relative error, RE) are within the range of −3.44 %-1.50 % and precisions are between 3.48 % and 10.19 %. μ-SPE could enrich the analytes and decrease the endogenous interferences, thereby improving the selectivity and sensitivity of the method. The analytical assay is selective, accurate and reproducible. The assay was successfully applied to therapeutic drug monitoring of vancomycin in clinical application.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"258 ","pages":"Article 116729"},"PeriodicalIF":3.1,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143453906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emodin-8-O-β-D-glucopyranoside alleviates cholestasis by maintaining intestinal homeostasis and regulating lipids and bile acids metabolism in mice

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis

Pub Date : 2025-02-04 DOI: 10.1016/j.jpba.2025.116734

Xiaolin Wu , Qiao Yu , Yuzhao Hou , Xuemei Zhang , Simon Sani Ocholi , Liming Wang , Ziping Yan , Jie Li , Lifeng Han

Cholestatic liver disease(CLD) is caused by impaired bile flow due to obstruction of the biliary tract, and long-term exposure to bile acids in the liver triggers inflammation, eventually leading to liver toxicity and liver fibrosis. Emodin-8-O-β-D-glucopyranoside(EG) is anthraquinone compound that is widely found in traditional Chinese medicine. It possessed antioxidative and anti-inflammatory activities. However, the effect of EG on cholestatic liver injury(CLI) has not been explored. In this study, Alpha-naphthyl isothiocyanate(ANIT)-induced CLI mice were used to investigate the anti-cholestasis and hepatoprotective effects of EG through serum biochemical index detection, non-targeted metabolomics, lipidomics, and intestinal flora 16S rRNA sequencing. The results suggested that EG restores homeostasis of the gut microbiome while regulating bile acids metabolism and lipid-related metabolic pathways to reduce liver damage in ANIT-induced cholestasis. This study provides a new perspective on the mechanism of EG, and help offer a more natural approach to managing liver damage.

{"title":"Emodin-8-O-β-D-glucopyranoside alleviates cholestasis by maintaining intestinal homeostasis and regulating lipids and bile acids metabolism in mice","authors":"Xiaolin Wu , Qiao Yu , Yuzhao Hou , Xuemei Zhang , Simon Sani Ocholi , Liming Wang , Ziping Yan , Jie Li , Lifeng Han","doi":"10.1016/j.jpba.2025.116734","DOIUrl":"10.1016/j.jpba.2025.116734","url":null,"abstract":"<div><div>Cholestatic liver disease(CLD) is caused by impaired bile flow due to obstruction of the biliary tract, and long-term exposure to bile acids in the liver triggers inflammation, eventually leading to liver toxicity and liver fibrosis. Emodin-8-<em>O-β</em>-D-glucopyranoside(EG) is anthraquinone compound that is widely found in traditional Chinese medicine. It possessed antioxidative and anti-inflammatory activities. However, the effect of EG on cholestatic liver injury(CLI) has not been explored. In this study, Alpha-naphthyl isothiocyanate(ANIT)-induced CLI mice were used to investigate the anti-cholestasis and hepatoprotective effects of EG through serum biochemical index detection, non-targeted metabolomics, lipidomics, and intestinal flora 16S rRNA sequencing. The results suggested that EG restores homeostasis of the gut microbiome while regulating bile acids metabolism and lipid-related metabolic pathways to reduce liver damage in ANIT-induced cholestasis. This study provides a new perspective on the mechanism of EG, and help offer a more natural approach to managing liver damage.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"258 ","pages":"Article 116734"},"PeriodicalIF":3.1,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143376965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of TRAF2, CAMK2G, and TIMM17A as biomarkers distinguishing mechanical asphyxia from sudden cardiac death base on 4D-DIA Proteomics: A pilot study

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis

Pub Date : 2025-02-03 DOI: 10.1016/j.jpba.2025.116730

Yuebing Huang, Hai Qiu, Wen Chen, Zilin Meng, Yu Cai, Dongfang Qiao, Xia Yue

In the context of forensic medicine, the differential diagnosis between mechanical asphyxia and sudden cardiac death is very important regarding the establishment of the cause of death. Traditional autopsy findings have generally been very nonspecific; accordingly, highlighting the need for more specific molecular biomarkers. This study employed four-dimensional data-independent acquisition (4D-DIA) proteomics technology, in combination with both animal models and human samples, to conduct a comprehensive protein expression analysis of cardiac tissues, identifying 7557 proteins, among which 142 shared differentially expressed proteins (DEPS) were screened out. Based on the protein interaction network and through rigorous screening, this study identified three proteins, namely TNF receptor-associated factor 2 (TRAF2), Calcium/calmodulin-dependent protein kinase II gamma (CAMK2G), and translocase of inner mitochondrial membrane 17 homolog A (TIMM17A), as biomarkers for differentiating mechanical asphyxia from sudden cardiac death. Further verification using Western Blot (WB) and immunohistochemistry (IHC) proved the differential expression of these biomarkers in both animal and human samples. These findings, besides deepening the molecular understanding of the pathophysiological differences between sudden cardiac death and mechanical asphyxia, also provided new biomarkers for forensic applications that could enable the improvement of accuracy and reliability in the determination of the cause of death.

{"title":"Identification of TRAF2, CAMK2G, and TIMM17A as biomarkers distinguishing mechanical asphyxia from sudden cardiac death base on 4D-DIA Proteomics: A pilot study","authors":"Yuebing Huang, Hai Qiu, Wen Chen, Zilin Meng, Yu Cai, Dongfang Qiao, Xia Yue","doi":"10.1016/j.jpba.2025.116730","DOIUrl":"10.1016/j.jpba.2025.116730","url":null,"abstract":"<div><div>In the context of forensic medicine, the differential diagnosis between mechanical asphyxia and sudden cardiac death is very important regarding the establishment of the cause of death. Traditional autopsy findings have generally been very nonspecific; accordingly, highlighting the need for more specific molecular biomarkers. This study employed four-dimensional data-independent acquisition (4D-DIA) proteomics technology, in combination with both animal models and human samples, to conduct a comprehensive protein expression analysis of cardiac tissues, identifying 7557 proteins, among which 142 shared differentially expressed proteins (DEPS) were screened out. Based on the protein interaction network and through rigorous screening, this study identified three proteins, namely TNF receptor-associated factor 2 (TRAF2), Calcium/calmodulin-dependent protein kinase II gamma (CAMK2G), and translocase of inner mitochondrial membrane 17 homolog A (TIMM17A), as biomarkers for differentiating mechanical asphyxia from sudden cardiac death. Further verification using Western Blot (WB) and immunohistochemistry (IHC) proved the differential expression of these biomarkers in both animal and human samples. These findings, besides deepening the molecular understanding of the pathophysiological differences between sudden cardiac death and mechanical asphyxia, also provided new biomarkers for forensic applications that could enable the improvement of accuracy and reliability in the determination of the cause of death.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"258 ","pages":"Article 116730"},"PeriodicalIF":3.1,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143289645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanomaterial-based electrochemical sensors for anti-HIV drug monitoring: Innovations, challenges, and prospects

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis

Pub Date : 2025-02-03 DOI: 10.1016/j.jpba.2025.116727

Abdellatif Ait Lahcen, Gymama Slaughter

Monitoring human immunodeficiency virus (HIV) and anti-HIV drugs is critical for optimizing treatment outcomes and preventing drug resistance. Accurate detection and quantification of anti-HIV drugs are essential to ensure appropriate dosing, enhancing patient care and therapeutic efficacy. Electrochemical biosensors have emerged as a pivotal tool in this context, offering high sensitivity, specificity, and rapid response times. Leveraging advancements in nanomaterials, these sensors provide reliable and efficient solutions for point-of-care (POC) applications in clinical and environmental settings. This review presents a comprehensive analysis of recent innovations in electrochemical sensor technologies for anti-HIV drug detection and quantification, focusing on nanomaterial-based platforms. It addresses the challenges of developing and implementing these technologies, including matrix effects, stability, and scalability. Furthermore, the review explores future directions, emphasizing the integration of sensors into POC systems and their potential to revolutionize personalized HIV treatment and pharmaceutical monitoring.

{"title":"Nanomaterial-based electrochemical sensors for anti-HIV drug monitoring: Innovations, challenges, and prospects","authors":"Abdellatif Ait Lahcen, Gymama Slaughter","doi":"10.1016/j.jpba.2025.116727","DOIUrl":"10.1016/j.jpba.2025.116727","url":null,"abstract":"<div><div>Monitoring human immunodeficiency virus (HIV) and anti-HIV drugs is critical for optimizing treatment outcomes and preventing drug resistance. Accurate detection and quantification of anti-HIV drugs are essential to ensure appropriate dosing, enhancing patient care and therapeutic efficacy. Electrochemical biosensors have emerged as a pivotal tool in this context, offering high sensitivity, specificity, and rapid response times. Leveraging advancements in nanomaterials, these sensors provide reliable and efficient solutions for point-of-care (POC) applications in clinical and environmental settings. This review presents a comprehensive analysis of recent innovations in electrochemical sensor technologies for anti-HIV drug detection and quantification, focusing on nanomaterial-based platforms. It addresses the challenges of developing and implementing these technologies, including matrix effects, stability, and scalability. Furthermore, the review explores future directions, emphasizing the integration of sensors into POC systems and their potential to revolutionize personalized HIV treatment and pharmaceutical monitoring.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"258 ","pages":"Article 116727"},"PeriodicalIF":3.1,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143179315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inter-individual variability in the metabolism of psychotropic drugs by the enzyme activities from the human gut microbiome

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis

Pub Date : 2025-02-01 DOI: 10.1016/j.jpba.2025.116717

Xuan Wang , Yuanfeng Lyu , Sau Wan Cheng , Tsz Fung Tsang , Ka Chun Chong , Siaw Shi Boon , Xiao Yang , Christopher KC Lai , Paul KS Chan , Zhong Zuo

The interaction between marketed drugs and the gut microbiome is increasingly being recognized, and it is now known that enzymes produced by the bacteria in the human gut can degrade psychotropic drugs. However, the degree of inter-individual variation in their metabolism remains largely unknown. Here, we present a simple model for detecting individual drug-microbiome interaction using fecalase. We incubated fecalase prepared from freshly collected stool samples from healthy volunteers (n = 18) and incubated with nine selected psychotropic medications. We proved fecalase retained enzymatic activities and showed the degree of drug degradation differed significantly for different psychotropic drugs, and there was significant inter-individual variation in the metabolism of phenytoin, amitriptyline, and chlorpromazine with the inter-individual point difference between the strongest and weakest metabolizer of 85 %, 39 %, and 30 % respectively. These findings highlight the potential of fecalase as a model for studying personalized drug metabolism and underscore the importance of considering gut microbiome variability in pharmacological research.

{"title":"Inter-individual variability in the metabolism of psychotropic drugs by the enzyme activities from the human gut microbiome","authors":"Xuan Wang , Yuanfeng Lyu , Sau Wan Cheng , Tsz Fung Tsang , Ka Chun Chong , Siaw Shi Boon , Xiao Yang , Christopher KC Lai , Paul KS Chan , Zhong Zuo","doi":"10.1016/j.jpba.2025.116717","DOIUrl":"10.1016/j.jpba.2025.116717","url":null,"abstract":"<div><div>The interaction between marketed drugs and the gut microbiome is increasingly being recognized, and it is now known that enzymes produced by the bacteria in the human gut can degrade psychotropic drugs. However, the degree of inter-individual variation in their metabolism remains largely unknown. Here, we present a simple model for detecting individual drug-microbiome interaction using fecalase. We incubated fecalase prepared from freshly collected stool samples from healthy volunteers (n = 18) and incubated with nine selected psychotropic medications. We proved fecalase retained enzymatic activities and showed the degree of drug degradation differed significantly for different psychotropic drugs, and there was significant inter-individual variation in the metabolism of phenytoin, amitriptyline, and chlorpromazine with the inter-individual point difference between the strongest and weakest metabolizer of 85 %, 39 %, and 30 % respectively. These findings highlight the potential of fecalase as a model for studying personalized drug metabolism and underscore the importance of considering gut microbiome variability in pharmacological research.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"258 ","pages":"Article 116717"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143352318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UHPLC-MS/MS-based analysis of 17 nitazenes in human hair for practical forensic casework with simultaneous separation of 6 groups of isomers

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis

Pub Date : 2025-01-31 DOI: 10.1016/j.jpba.2025.116707

Guoqing Gao , Shuo Yang , Xin Wang , Ping Xiang , Liting Ma , Fang Yan , Yan Shi

Nitazenes, a new class of potent synthetic opioids characterized by a 2-benzyl-benzimidazole structural core, have emerged on the illicit drug market following fentanyl. Compared to traditional opioids, nitazenes pose heightened risks of respiratory depression and central nervous system suppression. Due to the ease of modification of its parent nucleus, abusers and dealers can rapidly synthesize new structural analogs that fall outside the drug control catalog. Consequently, multiple isomers of nitazenes have emerged, causing significant interference in forensic practices. As an increasing number of poisoning and fatality cases were associated with nitazenes, there is an urgent need for developing an analytical method that can effectively address the challenges currently encountered in their identification in forensic practices. In this study, we established and validated a simple and high-efficiency ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for detecting 17 nitazenes in human hair. All analytes were separated in 6.5 min on a biphenyl column with simultaneous separation of six groups of isomers. Method validation demonstrated linear calibration over the range of 5–1000 pg/mg (r > 0.995), with limits of detection (LODs) ranging from 1 to 15 pg/mg and limits of quantification (LOQs) ranging from 5 to 20 pg/mg. The method also exhibited precision (<15 %) and accuracy ( ± 15 %), along with excellent recovery, acceptable matrix effects, and good stability at 4 ℃ for at least 72 h. When applied to authentic cases, this method successfully identified two positive hair samples and N,N-dimethylamino etonitazene was detected at concentrations of 1528.5 pg/mg and 463.9 pg/mg^, respectively. This method provides technical support for the rapid and accurate detection of nitazenes, better meeting the needs of anti-drug operations and forensic practice.

{"title":"UHPLC-MS/MS-based analysis of 17 nitazenes in human hair for practical forensic casework with simultaneous separation of 6 groups of isomers","authors":"Guoqing Gao , Shuo Yang , Xin Wang , Ping Xiang , Liting Ma , Fang Yan , Yan Shi","doi":"10.1016/j.jpba.2025.116707","DOIUrl":"10.1016/j.jpba.2025.116707","url":null,"abstract":"<div><div>Nitazenes, a new class of potent synthetic opioids characterized by a 2-benzyl-benzimidazole structural core, have emerged on the illicit drug market following fentanyl. Compared to traditional opioids, nitazenes pose heightened risks of respiratory depression and central nervous system suppression. Due to the ease of modification of its parent nucleus, abusers and dealers can rapidly synthesize new structural analogs that fall outside the drug control catalog. Consequently, multiple isomers of nitazenes have emerged, causing significant interference in forensic practices. As an increasing number of poisoning and fatality cases were associated with nitazenes, there is an urgent need for developing an analytical method that can effectively address the challenges currently encountered in their identification in forensic practices. In this study, we established and validated a simple and high-efficiency ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for detecting 17 nitazenes in human hair. All analytes were separated in 6.5 min on a biphenyl column with simultaneous separation of six groups of isomers. Method validation demonstrated linear calibration over the range of 5–1000 pg/mg (r > 0.995), with limits of detection (LODs) ranging from 1 to 15 pg/mg and limits of quantification (LOQs) ranging from 5 to 20 pg/mg. The method also exhibited precision (<15 %) and accuracy ( ± 15 %), along with excellent recovery, acceptable matrix effects, and good stability at 4 ℃ for at least 72 h. When applied to authentic cases, this method successfully identified two positive hair samples and N,N-dimethylamino etonitazene was detected at concentrations of 1528.5 pg/mg and 463.9 pg/mg<sup>,</sup> respectively. This method provides technical support for the rapid and accurate detection of nitazenes, better meeting the needs of anti-drug operations and forensic practice.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"257 ","pages":"Article 116707"},"PeriodicalIF":3.1,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143161411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of pharmaceutical and biomedical analysis

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀